Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

January 8, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805421/0/en/Vera-Therapeutics-Announces-Appointment-of-Industry-Veterans-Robert-Brenner-M-D-as-Chief-Medical-Officer-and-William-D-Turner-as-Chief-Development-Officer.html

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq:VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the appointments of two industry veterans to help lead the development of the company’s drug programs including its late-stage product candidate, atacicept, to treat autoimmune diseases, currently in a Phase 3 clinical trial for IgA nephropathy (IgAN). The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.; and William D. Turner as Chief Development Officer, effective immediately.

Read more at globenewswire.com

Related news for (VERA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.